Predictive Factors Of Appropriate Shock Therapy...

The Prevalence Of Arterial Hypertension In Samp...

Massive Pulmonary Embolism Associated With Hemo...

Blood, Sweat, And Tears. Angiogenesis, Angiogen...

Lcz696 An Innovation For Heart Failure

0 votes
Tailored Therapy For Heart Failure Based On Genetic Variations
Author: Grazia Daniela Femminella, Vincenzo Barrese, Nicola Ferrara, Giuseppe Rengo
7 pages
One time payment: €0.00
Required subscription: Free
Type of publication: Article
ISBN/ISSN: 1178-7066
DOI: 10.2147/49799
Follow this publisher

Share this publication:


Abstract: Heart failure is one of the leading causes of mortality in Western countries, and β-blockers are a cornerstone of its treatment. However, the response to these drugs is variable among individuals, which might be explained, at least in part, by genetic differences. Pharmacogenomics is the study of genetic contributions to drug response variability in order to provide evidence for a tailored therapy in an individual patient. Several studies have investigated the pharmacogenomics of the adrenergic receptor system and its role in the context of the use of β-blockers in treating heart failure. In this review, we will focus on the most significant polymorphisms described in the literature involving adrenergic receptors and adrenergic receptor-related proteins, as well as genetic variations influencing β-blocker metabolism.

Select a payment method